|
|
Blood, 15 February 2008, Vol. 111, No. 4, pp. 2112-2121.
Prepublished online as a Blood First Edition Paper on December 6, 2007; DOI 10.1182/blood-2007-06-096586.
 Previous Article | Next Article 
Submitted June 19, 2007
Accepted November 27, 2007
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem cell transplantation
Paria Mirmonsef, Gladys Tan, Gang Zhou, Tricia Morino, Kimberly Noonan, Ivan Borrello, and Hyam I. Levitsky*
Immunology & Hematopoiesis, Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States
Microbiology, Defense Medical and Environmental Research Institute, Singapore
* Corresponding author; email: hy{at}jhmi.edu.
Immune reconstitution of autologous hematopoietic stem-cell transplant recipients with the progeny of mature T cells in the graft leads to profound changes in the emerging functional T cell repertoire. In the steady-state, the host is frequently tolerant to tumor-antigens, reflecting dominant suppression of naive and effector T cells by regulatory T cells (Tregs). We examined the relative frequency and function of these three components within the tumor-specific T cell compartment during immune reconstitution. Grafts from tumor-bearing donors exerted a significant anti-tumor effect in irradiated, syngeneic tumor-bearing recipients. This was associated with dramatic clonal expansion and interferon- (IFN) production by previously tolerant tumor-specific T cells. While donor-derived Tregs expanded in recipients, they did not inhibit the antigen-driven expansion of effector T cells in the early post-transplant period. Indeed, the repopulation of tumor-specific effector T cells significantly exceeded that of Tregs, the expansion of which was limited by IL-2 availability. Although the intrinsic suppressive capacity of Tregs remained intact, their diminished frequency was insufficient to suppress effector cell function. These findings provide an explanation for the reversal of tolerance leading to tumor rejection in transplant recipients and likely contribute to the efficacy of adoptive T cell therapies in lymphopenic hosts.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Filatenkov, A. M. S. Muller, W. W.-L. Tseng, S. Dejbakhsh-Jones, D. Winer, R. Luong, J. A. Shizuru, E. G. Engleman, and S. Strober
Ineffective Vaccination against Solid Tumors Can Be Enhanced by Hematopoietic Cell Transplantation
J. Immunol.,
December 1, 2009;
183(11):
7196 - 7203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. T. Ho, M. Vanneman, H. Kim, T. Sasada, Y. J. Kang, M. Pasek, C. Cutler, J. Koreth, E. Alyea, S. Sarantopoulos, et al.
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation
PNAS,
September 15, 2009;
106(37):
15825 - 15830.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Horkheimer, M. Quigley, J. Zhu, X. Huang, N. J. Chao, and Y. Yang
Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation
Blood,
May 21, 2009;
113(21):
5330 - 5339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Brody, M. J. Goldstein, D. K. Czerwinski, and R. Levy
Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors
Blood,
January 1, 2009;
113(1):
85 - 94.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
